Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 16Cyclophosphamide 13fludarabine phosphate 9Mycophenolic Acid 9venetoclax 8Methotrexate 8Antilymphocyte Serum 8Tacrolimus 7Cyclosporine 7Busulfan 7Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5Decitabine 5Cord Blood Stem Cell Transplantation 5Rituximab 4Arsenic Trioxide 4Sunitinib 3Sorafenib 3Methylprednisolone 3Melphalan 3Leucovorin 3Clofarabine 3ruxolitinib 2ponatinib 2idelalisib 2Sirolimus 2Moxifloxacin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelomonocytic, Chronic × ASTX-660 × Clear all
NCT04155580 2024-08-02

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Astex Pharmaceuticals, Inc.

Phase 1 Terminated
68 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡